ClinicalTrials.gg
CompletedNCT00625547Updated Oct 29, 2008

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

A Phase 3 interventional study of cabergoline and levodopa in Restless Legs Syndrome, sponsored by Pfizer. Completed at 50 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-10-29.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Restless Legs Syndrome with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Restless Legs Syndrome · Germany.

Enrollment
7th of 22
361 · median 316
Started
2003
with 2 others
Phase 3
11 of 28
none open now
Registered
19th of 28
by date
Lead sponsor
1 of 28
Pfizer

Among the 28 studies in Restless Legs Syndrome with a site in Germany, this one is the 7th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2003, is one of 11 in phase 3, and was the 19th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

1 of the 28 studies in Restless Legs Syndrome with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Restless Legs Syndrome with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of idiopathic RLS and had all 4 clinical manifestations of RLS
  • Moderate to severe symptoms of RLS as indicated by an IRLSSG-RS total score greater than or equal to 10 and a severity at night score of greater than or equal to 4 on an 11-point RLS-6 rating scale
  • No previous treatment for RLS or dissatisfaction with their current therapy

Exclusion criteria

Exclusion Criteria:

  • Not available
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    1

    Drug: cabergoline

  • Experimental
    2

    Drug: levodopa

Interventions

  • Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events

  • Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events

06

What researchers measure

Primary outcomes

  1. Change from baseline in the total score of the International RLS Study Group Rating Scale (IRLSSG-RS)

    Time frame: Week 6

  2. Time to dropout due to a necessary change in RLS therapy because of augmentation or loss of efficacy (e.g., dose increment of study drug, switch to another therapy, or start of a drug-free period)

Secondary outcomes

  1. RLS quality-of-life questionnaire

    Time frame: Weeks 6 and 30

  2. Clinical Global Impression

    Time frame: Weeks 6 and 30

  3. Patient Global Impression

    Time frame: Weeks 6 and 30

  4. Sleep questionnaire form A

    Time frame: Weeks 6 and 30

  5. IRLSSG-RS

    Time frame: Week 30

  6. Safety evaluation including adverse events, clinically relevant changes in laboratory data, physical exam findings, and abnormalities observed in electrocardiogram

    Time frame: Weeks 2, 6, and 8 during Period 1 and every 4 weeks during Period 2

  7. Rating of severity of RLS at night (RLS-6 scale)

    Time frame: Weeks 6 and 30

  8. Rating of severity of RLS before bedtime (RLS-6 scale)

    Time frame: Weeks 6 and 30

  9. Rating of severity of RLS at day when at rest and during activities, severity of daytime sleepiness (RLS-6 scales)

    Time frame: Weeks 6 and 30

  10. Global rating of quality of sleep (RLS-6 scale)

    Time frame: Weeks 6 and 30

07

Study locations

50 sites
  • Pfizer Investigational Site
    Innsbruck, 6020, Austria
  • Pfizer Investigational Site
    Wien, A-1090, Austria
  • Pfizer Investigational Site
    Altoetting, 84503, Germany
  • Pfizer Investigational Site
    Aschaffenburg, 63739, Germany
  • Pfizer Investigational Site
    Bad Honnef, 53604, Germany
  • Pfizer Investigational Site
    Bad Saarow, 15526, Germany
  • Pfizer Investigational Site
    Beckum, 49269, Germany
  • Pfizer Investigational Site
    Berlin, 10969, Germany
  • Pfizer Investigational Site
    Berlin, 12163, Germany
  • Pfizer Investigational Site
    Berlin, 12687, Germany
  • Pfizer Investigational Site
    Berlin, 13053, Germany
  • Pfizer Investigational Site
    Berlin, 13507, Germany
  • Pfizer Investigational Site
    Bochum, Germany
  • Pfizer Investigational Site
    Bremerhaven, 27568, Germany
  • Pfizer Investigational Site
    Dillingen, 66763, Germany
  • Pfizer Investigational Site
    Duesseldorf, 40211, Germany
  • Pfizer Investigational Site
    Duisburg, Germany
  • Pfizer Investigational Site
    Gelsenkirchen, 45891, Germany
  • Pfizer Investigational Site
    Gera, 0755, Germany
  • Pfizer Investigational Site
    Goettingen, 37037, Germany
  • Pfizer Investigational Site
    Goettingen, 37075, Germany
  • Pfizer Investigational Site
    Halle, 06118, Germany
  • Pfizer Investigational Site
    Hamburg, 22359, Germany
  • Pfizer Investigational Site
    Heilbronn, 74072, Germany
  • Pfizer Investigational Site
    Jena, Germany
  • Pfizer Investigational Site
    Kaiserslautern, 67655, Germany
  • Pfizer Investigational Site
    Karlsruhe, 76137, Germany
  • Pfizer Investigational Site
    Karlsruhe, Germany
  • Pfizer Investigational Site
    Kassel, 34128, Germany
  • Pfizer Investigational Site
    Köthen, Germany
  • Pfizer Investigational Site
    Marburg, 35039, Germany
  • Pfizer Investigational Site
    Mittweida, 09648, Germany
  • Pfizer Investigational Site
    Moenchengladbach, 41179, Germany
  • Pfizer Investigational Site
    Neubrandenburg, 17033, Germany
  • Pfizer Investigational Site
    Oldenburg, 26122, Germany
  • Pfizer Investigational Site
    Quickborn, 25451, Germany
  • Pfizer Investigational Site
    Regensburg, 93053, Germany
  • Pfizer Investigational Site
    Schwalmstadt, 34613, Germany
  • Pfizer Investigational Site
    Schwerin, 19055, Germany
  • Pfizer Investigational Site
    Stuttgart, 70176, Germany
  • Pfizer Investigational Site
    Tuttlingen, 78532, Germany
  • Pfizer Investigational Site
    Ulm, 89073, Germany
  • Pfizer Investigational Site
    Wiesbaden, 65191, Germany
  • Pfizer Investigational Site
    Wolfsburg, Germany
  • Pfizer Investigational Site
    Goteborg, S-413 45, Sweden
  • Pfizer Investigational Site
    Karlstad, Sweden
  • Pfizer Investigational Site
    Linköping, 581 85, Sweden
  • Pfizer Investigational Site
    Basel, 4031, Switzerland
  • Pfizer Investigational Site
    Bern, Switzerland
  • Pfizer Investigational Site
    Zürich, CH-8091, Switzerland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2008
First posted
Feb 28, 2008
Start
Jan 2003
CompletionActual
Dec 2004
Last update
Oct 29, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00625547
Lead sponsor
Pfizer
First posted
Feb 28, 2008
Start date
Jan 2003
Completion
Dec 2004
Last update
Oct 29, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabergoline · Levodopa

Start the discussion